Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
AbstractThe concept of utilizing polymers in drug delivery has been extensively explored for improving the therapeutic index of small molecule drugs. In general, polymers can be used as polymer-drug conjugates or polymeric micelles. Each unique application mandates its own chemistry and controlled release of active drugs. Each polymer exhibits its own intrinsic issues providing the advantage of flexibility. However, none have as yet been approved by the U.S. Food and Drug Administration. General aspects of polymer and nano-particle therapeutics have been reviewed. Here we focus this review on specific clinically relevant anticancer polymer paclitaxel therapeutics. We emphasize their chemistry and formulation, in vitro activity on some human cancer cell lines, plasma pharmacokinetics and tumor accumulation, in vivo efficacy, and clinical outcomes. Furthermore, we include a short review of our recent developments of a novel poly(L-g-glutamylglutamine)-paclitaxel nano-conjugate (PGG-PTX). PGG-PTX has its own unique property of forming nano-particles. It has also been shown to possess a favorable profile of pharmacokinetics and to exhibit efficacious potency. This review might shed light on designing new and better polymer paclitaxel therapeutics for potential anticancer applications in the clinic. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Yang, D.; Yu, L.; Van, S. Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics. Cancers 2011, 3, 17-42.
Yang D, Yu L, Van S. Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics. Cancers. 2011; 3(1):17-42.Chicago/Turabian Style
Yang, Danbo; Yu, Lei; Van, Sang. 2011. "Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics." Cancers 3, no. 1: 17-42.